To this end, we tested the minimal dose of herbal extracts (IC90 for the NSCLC cell line H1299 in this study) for EFHD2 inhibition to reduce adverse effects, such as herb-drug interactions, which may alter the systemic bioavailability and pharmacokinetics of these drugs. This evidence concerns the gene EFHD2 and non-small cell lung carcinoma.